IRIS

Selenium and Compounds

CASRN 7782-49-2

Noncancer Assessment

Reference Dose for Oral Exposure (RfD) (PDF) (24 pp, 166 K) last updated: 06/01/1991

System RfD (mg/kg-day) Basis PoD Composite UF Confidence
Nervous, Hematologic, Dermal 5 x 10-3 Clinical selenosis NOAEL : 1.5 x 10-2
mg/kg-day
3 High

 


Reference Concentration for Inhalation Exposure (RfC) (PDF) (24 pp, 166 K)
Not assessed under the IRIS Program.

 

Cancer Assessment

Weight of Evidence for Cancer (PDF) (24 pp, 166 K) last updated: 03/01/1991

WOE Characterization Framework for WOE Characterization
D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (US EPA, 1986)
Basis:
  • Based on inadequate human data and inadequate evidence of carcinogenicity in animals. The evidence for various selenium compounds in animal and mutagenicity studies is conflicting and difficult to interpret; however, evidence for selenium sulfide is sufficient for a B2 (probable human carcinogen) classification.
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (24 pp, 166 K)

Not assessed under the IRIS Program.

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (24 pp, 166 K)

Not assessed under the IRIS Program.

You will need Adobe Reader to view some of the files on this page. See EPA’s PDF page to learn more.